{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:09:15Z","timestamp":1791940155763,"version":"4.3.4"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"51","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Environ Sci Pollut Res"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11356-022-23043-3","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T12:03:00Z","timestamp":1664193780000},"page":"76514-76531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Insights into the pivotal role of statins and its nanoformulations in hyperlipidemia"],"prefix":"10.1007","volume":"29","author":[{"given":"Sukhbir","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishrat","family":"Zahoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Kanojia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syam","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosif","family":"Almoshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Salawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Aleya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"23043_CR1","doi-asserted-by":"publisher","first-page":"111494","DOI":"10.1016\/j.biopha.2021.111494","volume":"139","author":"HB Abo-zalam","year":"2021","unstructured":"Abo-zalam HB, El-Denshary ES, Abdelsalam RM, Khalil IA, Khattab MM, Hamzawy MA (2021) Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: comprehensive study. Biomed Pharmacother 139:111494. https:\/\/doi.org\/10.1016\/j.biopha.2021.111494","journal-title":"Biomed Pharmacother"},{"key":"23043_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5530\/ijpi.2020.2.29","volume":"10","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Gautam G (2020) Formulation, development and characterization of ethosomes of atorvastatin. Int J Pharm Investig 10:156\u2013159. https:\/\/doi.org\/10.5530\/ijpi.2020.2.29","journal-title":"Int J Pharm Investig"},{"key":"23043_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijpharm.2016.03.045","volume":"504","author":"IS Ahmed","year":"2016","unstructured":"Ahmed IS, El-Hosary R, Shalaby S, Abd-Rabo MM, Elkhateeb DG, Nour S (2016) PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-\u03b5-caprolactone nanoparticles. Int J Pharm 504:70\u201379. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.03.045","journal-title":"Int J Pharm"},{"key":"23043_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-020-0393-8","volume":"21","author":"TA Ahmed","year":"2020","unstructured":"Ahmed TA (2020) Development of rosuvastatin flexible lipid-based nanoparticles: promising nanocarriers for improving intestinal cells cytotoxicity. BMC Pharmacol Toxicol 21:1\u20132. https:\/\/doi.org\/10.1186\/s40360-020-0393-8","journal-title":"BMC Pharmacol Toxicol"},{"key":"23043_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jddst.2018.10.027","volume":"48","author":"TA Ahmed","year":"2018","unstructured":"Ahmed TA, Badr-Eldin SM, Ahmed OA, Aldawsari H (2018) Intranasal optimized solid lipid nanoparticles loaded in situ gel for enhancing trans-mucosal delivery of simvastatin. J Drug Deliv Sci Technol 48:499\u2013508. https:\/\/doi.org\/10.1016\/j.jddst.2018.10.027","journal-title":"J Drug Deliv Sci Technol"},{"key":"23043_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/03639045.2018.1515221","volume":"45","author":"S Aldalaen","year":"2019","unstructured":"Aldalaen S, El-Gogary RI, Nasr M (2019) Fabrication of rosuvastatin-loaded polymeric nanocapsules: a promising modality for treating hepatic cancer delineated by apoptotic and cell cycle arrest assessment. Drug Dev Ind Pharm 45:55\u201362. https:\/\/doi.org\/10.1080\/03639045.2018.1515221","journal-title":"Drug Dev Ind Pharm"},{"key":"23043_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1074248408328927","volume":"14","author":"KP Alexander","year":"2009","unstructured":"Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS, Smith SC Jr, Ohman EM (2009) Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther 14:49\u201358. https:\/\/doi.org\/10.1177\/1074248408328927","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"23043_CR8","doi-asserted-by":"publisher","first-page":"119106","DOI":"10.1016\/j.ijpharm.2020.119106","volume":"578","author":"FN Al-Heibshy","year":"2020","unstructured":"Al-Heibshy FN, Ba\u015faran E, Arslan R, \u00d6zt\u00fcrk N, Erol K, Demirel M (2020) Physicochemical characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated solid lipid nanoparticles. Int J Pharm 578:119106. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119106","journal-title":"Int J Pharm"},{"key":"23043_CR9","doi-asserted-by":"publisher","first-page":"e0200218","DOI":"10.1371\/journal.pone.0200218","volume":"13","author":"DH Alshora","year":"2018","unstructured":"Alshora DH, Ibrahim MA, Elzayat E, Almeanazel OT, Alanazi F (2018) Rosuvastatin calcium nanoparticles: improving bioavailability by formulation and stabilization codesign. PLoS ONE 13:e0200218. https:\/\/doi.org\/10.1371\/journal.pone.0200218","journal-title":"PLoS ONE"},{"key":"23043_CR10","first-page":"14","volume":"1","author":"R Ankita","year":"2013","unstructured":"Ankita R, Ganesh B, Preeti K (2013) Formulation and evaluation of nanosuspension of rosuvastatin calcium. Int J Drug Regul Aff 1:14\u201318","journal-title":"Int J Drug Regul Aff"},{"key":"23043_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/IJN.S237314","volume":"15","author":"MG Arafa","year":"2020","unstructured":"Arafa MG, Girgis GN, El-Dahan MS (2020) Chitosan-coated PLGA nanoparticles for enhanced ocular anti-inflammatory efficacy of atorvastatin calcium. Int J Nanomedicine 15:1335. https:\/\/doi.org\/10.2147\/IJN.S237314","journal-title":"Int J Nanomedicine"},{"key":"23043_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.36468\/pharmaceutical-sciences.620","volume":"82","author":"S Arjun","year":"2020","unstructured":"Arjun S, Karthik S, Arjunan K, Hariharan S, Seenivasan P, Sankar V (2020) Preparation and evaluation of rosuvastatin calcium nanosuspension and solid dispersion tablets by wet granulation and direct compression techniques using tamarind gum as a binder. Indian J Pharm Sci 82:32\u201340. https:\/\/doi.org\/10.36468\/pharmaceutical-sciences.620","journal-title":"Indian J Pharm Sci"},{"key":"23043_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jddst.2016.01.004","volume":"32","author":"MM Badran","year":"2016","unstructured":"Badran MM, Harisa GI, AlQahtani SA, Alanazi FK, Zoheir KM (2016) Pravastatin-loaded chitosan nanoparticles: formulation, characterization and cytotoxicity studies. J Drug Deliv Sci Technol 32:1\u20139. https:\/\/doi.org\/10.1016\/j.jddst.2016.01.004","journal-title":"J Drug Deliv Sci Technol"},{"key":"23043_CR14","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1210\/jcem.85.6.6642-1","volume":"85","author":"CM Ballantyne","year":"2000","unstructured":"Ballantyne CM, Grundy SM, Oberman A, Kreisberg RA, Havel RJ (2000) Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 85:2089\u20132112. https:\/\/doi.org\/10.1210\/jcem.85.6.6642-1","journal-title":"J Clin Endocrinol Metab"},{"key":"23043_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2021.01.009","volume":"320","author":"M Banach","year":"2021","unstructured":"Banach M, Penson PE (2021) Lipid-lowering therapies: better together. Atherosclerosis 320:86\u201388. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.01.009","journal-title":"Atherosclerosis"},{"key":"23043_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jddst.2015.07.003","volume":"29","author":"Y Ba\u015fp\u0131nar","year":"2015","unstructured":"Ba\u015fp\u0131nar Y, G\u00fcndo\u011fdu E, K\u00f6ksal \u00c7, Karasulu E (2015) Pitavastatin-containing nanoemulsions: preparation, characterization and in vitro cytotoxicity. J Drug Deliv Sci Technol 29:117\u2013124. https:\/\/doi.org\/10.1016\/j.jddst.2015.07.003","journal-title":"J Drug Deliv Sci Technol"},{"key":"23043_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2217\/nnm-2016-0336","volume":"12","author":"S Beg","year":"2017","unstructured":"Beg S, Jain S, Kushwah V, Bhatti GK, Sandhu PS, Katare OP, Singh B (2017) Novel surface-engineered solid lipid nanoparticles of rosuvastatin calcium for low-density lipoprotein-receptor targeting: a quality by design-driven perspective. Nanomedicine 12:333\u2013356. https:\/\/doi.org\/10.2217\/nnm-2016-0336","journal-title":"Nanomedicine"},{"key":"23043_CR18","doi-asserted-by":"publisher","first-page":"8173","DOI":"10.1039\/C5RA24278A","volume":"6","author":"S Beg","year":"2016","unstructured":"Beg S, Raza K, Kumar R, Chadha R, Katare OP, Singh B (2016) Improved intestinal lymphatic drug targeting via phospholipid complex-loaded nanolipospheres of rosuvastatin calcium. RSC Adv 6:8173\u20138187. https:\/\/doi.org\/10.1039\/C5RA24278A","journal-title":"RSC Adv"},{"key":"23043_CR19","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.21746\/ijcls.2017.5.1","volume":"6","author":"A Beniwal","year":"2019","unstructured":"Beniwal A, Choudhary HC (2019) Rosuvastatin calcium-loaded solid lipid nanoparticles (SLN) using design of experiment approach for oral delivery. Int J Chem Life Sci 6:2029\u20132038","journal-title":"Int J Chem Life Sci"},{"key":"23043_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/1753-0407.12970","volume":"12","author":"JK Beverly","year":"2020","unstructured":"Beverly JK, Budoff MJ (2020) Atherosclerosis: pathophysiology of insulin resistance, hyperglycemia, Hyperlipidemia, and inflammation. J Diabetes 12:102\u2013104. https:\/\/doi.org\/10.1111\/1753-0407.12970","journal-title":"J Diabetes"},{"key":"23043_CR21","first-page":"113","volume":"2","author":"ST Bhagawati","year":"2017","unstructured":"Bhagawati ST, Varsha NS (2017) Formulation and in-vitro evaluation of pravastatin solid lipid nanoparticles. Int J Nano Med & Eng 2:113\u2013119","journal-title":"Int J Nano Med & Eng"},{"key":"23043_CR22","doi-asserted-by":"publisher","first-page":"a993","DOI":"10.1136\/bmj.a993","volume":"337","author":"D Bhatnagar","year":"2008","unstructured":"Bhatnagar D, Soran H, Durrington PN (2008) Hypercholesterolaemia and its management. BMJ 337:a993. https:\/\/doi.org\/10.1136\/bmj.a993","journal-title":"BMJ"},{"key":"23043_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43094-019-0008-7","volume":"5","author":"RS Brito","year":"2019","unstructured":"Brito RS, Chandrasekhar KB, Reddy KB (2019) Formulation, in-vitro and in-vivo pharmacokinetic evaluation of simvastatin nanostructured lipid carrier loaded transdermal drug delivery system. Futur J Pharm Sci 5:1\u20134. https:\/\/doi.org\/10.1186\/s43094-019-0008-7","journal-title":"Futur J Pharm Sci"},{"key":"23043_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2012.15","volume":"8","author":"MC Brouwers","year":"2012","unstructured":"Brouwers MC, Van Greevenbroek MM, Stehouwer CD, De Graaf J, Stalenhoef AF (2012) The genetics of familial combined hyperlipidemia. Nat Rev Endocrinol 8:352\u2013362. https:\/\/doi.org\/10.1038\/nrendo.2012.15","journal-title":"Nat Rev Endocrinol"},{"key":"23043_CR25","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2165\/00003495-200262140-00008","volume":"62","author":"CI Carswell","year":"2002","unstructured":"Carswell CI, Plosker GL, Jarvis B (2002) Rosuvastatin. Drugs 62:2075\u20132085. https:\/\/doi.org\/10.2165\/00003495-200262140-00008","journal-title":"Drugs"},{"key":"23043_CR26","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ejim.2009.06.005","volume":"20","author":"L Castilla-Guerra","year":"2009","unstructured":"Castilla-Guerra L, del Carmen F-M, \u00c1lvarez-Suero J (2009) Secondary stroke prevention in the elderly: new evidence in hypertension and hyperlipidemia. Eur J Intern Med 20:586\u2013590. https:\/\/doi.org\/10.1016\/j.ejim.2009.06.005","journal-title":"Eur J Intern Med"},{"key":"23043_CR27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3109\/02652048.2013.788085","volume":"30","author":"SS Chavhan","year":"2013","unstructured":"Chavhan SS, Petkar KC, Sawant KK (2013) Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. J Microencapsul 30:771\u2013779. https:\/\/doi.org\/10.3109\/02652048.2013.788085","journal-title":"J Microencapsul"},{"key":"23043_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-020-01275-x","volume":"19","author":"I Crismaru","year":"2020","unstructured":"Crismaru I, Stoian AP, Bratu OG, Gaman MA, Stanescu AM, Bacalbasa N, Diaconu CC (2020) Low-density lipoprotein cholesterol lowering treatment: the current approach. Lipids Health Dis 19:1\u201310. https:\/\/doi.org\/10.1186\/s12944-020-01275-x","journal-title":"Lipids Health Dis"},{"key":"23043_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1517\/17425255.4.6.821","volume":"4","author":"AI del Sol","year":"2008","unstructured":"del Sol AI, Nanayakkara PW (2008) Pravastatin: an evidence-based statin? Expert Opin Drug Metab Toxicol 4:821\u2013825. https:\/\/doi.org\/10.1517\/17425255.4.6.821","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"23043_CR30","first-page":"112","volume":"1","author":"KA Dhoranwala","year":"2015","unstructured":"Dhoranwala KA, Shah P, Shah S (2015) Formulation optimization of rosuvastatin calcium-loaded solid lipid nanoparticles by 32 Full-factorial design. NanoWorld J 1:112\u2013121","journal-title":"NanoWorld J"},{"key":"23043_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.pedhc.2020.11.007","volume":"35","author":"S Dombalis","year":"2021","unstructured":"Dombalis S, Nash A (2021) The effect of statins in children and adolescents with familial hypercholesterolemia: a systematic review. J Pediatr Health Care 35:292\u2013303. https:\/\/doi.org\/10.1016\/j.pedhc.2020.11.007","journal-title":"J Pediatr Health Care"},{"key":"23043_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejpb.2016.10.022","volume":"110","author":"N Dudhipala","year":"2017","unstructured":"Dudhipala N, Veerabrahma K (2017) Improved anti-hyperlipidemic activity of Rosuvastatin calcium via lipid nanoparticles: pharmacokinetic and pharmacodynamic evaluation. Eur J Pharm Biopharm 110:47\u201357. https:\/\/doi.org\/10.1016\/j.ejpb.2016.10.022","journal-title":"Eur J Pharm Biopharm"},{"key":"23043_CR33","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.pop.2005.09.002","volume":"32","author":"CB Eaton","year":"2005","unstructured":"Eaton CB (2005) Hyperlipidemia. Prim Care 32:1027\u20131055. https:\/\/doi.org\/10.1016\/j.pop.2005.09.002","journal-title":"Prim Care"},{"key":"23043_CR34","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1080\/10717544.2017.1337823","volume":"24","author":"M Elmowafy","year":"2017","unstructured":"Elmowafy M, Ibrahim HM, Ahmed MA, Shalaby K, Salama A, Hefesha H (2017) Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug Deliv 24:932\u2013941. https:\/\/doi.org\/10.1080\/10717544.2017.1337823","journal-title":"Drug Deliv"},{"key":"23043_CR35","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s13346-020-00761-0","volume":"10","author":"I Elsayed","year":"2020","unstructured":"Elsayed I, El-Dahmy RM, El-Emam SZ, Elshafeey AH, El Gawad NA, El-Gazayerly ON (2020) Response surface optimization of biocompatible elastic nanovesicles loaded with rosuvastatin calcium: enhanced bioavailability and anticancer efficacy. Drug Deliv Transl Res 10:1459\u20131475. https:\/\/doi.org\/10.1007\/s13346-020-00761-0","journal-title":"Drug Deliv Transl Res"},{"key":"23043_CR36","doi-asserted-by":"publisher","first-page":"e16412","DOI":"10.7759\/cureus.16412","volume":"13","author":"KJ Ezeh","year":"2021","unstructured":"Ezeh KJ, Ezeudemba O (2021) Hyperlipidemia: a review of the novel methods for the management of lipids. Cureus 13:e16412. https:\/\/doi.org\/10.7759\/cureus.16412","journal-title":"Cureus"},{"key":"23043_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/medicina55090579","volume":"55","author":"SA Faran","year":"2019","unstructured":"Faran SA, Asghar S, Khalid SH, Khan IU, Asif M, Khalid I, Farooq Gohar U, Hussain T (2019) Hepatoprotective and renoprotective properties of lovastatin-loaded ginger and garlic oil nanoemulsomes: insights into serum biological parameters. Medicina 55:579. https:\/\/doi.org\/10.3390\/medicina55090579","journal-title":"Medicina"},{"key":"23043_CR38","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jsps.2020.11.012","volume":"28","author":"TM Faris","year":"2020","unstructured":"Faris TM, Harisa GI, Alanazi FK, Samy AM, Nasr FA (2020) Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability. Saudi Pharm J 28:1851\u20131867. https:\/\/doi.org\/10.1016\/j.jsps.2020.11.012","journal-title":"Saudi Pharm J"},{"key":"23043_CR39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.colsurfb.2017.11.064","volume":"162","author":"HA Fathi","year":"2018","unstructured":"Fathi HA, Allam A, Elsabahy M, Fetih G, El-Badry M (2018) Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B Biointerfaces 162:236\u2013245. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.11.064","journal-title":"Colloids Surf B Biointerfaces"},{"key":"23043_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-020-00844-w","volume":"22","author":"N Ferri","year":"2020","unstructured":"Ferri N, Corsini A (2020) Clinical pharmacology of statins: an update. Curr Atheroscler Rep 22:1\u20139. https:\/\/doi.org\/10.1007\/s11883-020-00844-w","journal-title":"Curr Atheroscler Rep"},{"key":"23043_CR41","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.2147\/IJN.S241120","volume":"15","author":"DA Gaber","year":"2020","unstructured":"Gaber DA (2020) Nanoparticles of lovastatin: design, optimization and in vivo evaluation. Int J Nanomedicine 15:4225. https:\/\/doi.org\/10.2147\/IJN.S241120","journal-title":"Int J Nanomedicine"},{"key":"23043_CR42","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1016\/j.xphs.2017.04.060","volume":"106","author":"MM Gabr","year":"2017","unstructured":"Gabr MM, Mortada SM, Sallam MA (2017) Hexagonal liquid crystalline nanodispersions proven superiority for enhanced oral delivery of rosuvastatin: in vitro characterization and in vivo pharmacokinetic study. J Pharm Sci 106:3103\u20133112. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.060","journal-title":"J Pharm Sci"},{"key":"23043_CR43","doi-asserted-by":"publisher","first-page":"605","DOI":"10.5530\/ijper.50.4.13","volume":"50","author":"AP Gadad","year":"2016","unstructured":"Gadad AP, Tigadi SG, Dandagi PM, Mastiholimath VS, Bolmal UB (2016) Rosuvastatin loaded nanostructured lipid carrier: for enhancement of oral bioavailability. Indian J Pharm Educ Res 50:605\u2013611","journal-title":"Indian J Pharm Educ Res"},{"key":"23043_CR44","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1080\/03639045.2018.1492605","volume":"44","author":"VM Gambhire","year":"2018","unstructured":"Gambhire VM, Salunkhe SM, Gambhire MS (2018) Atorvastatin-loaded lipid nanoparticles: antitumor activity studies on MCF-7 breast cancer cells. Drug Dev Ind Pharm 44:1685\u20131692. https:\/\/doi.org\/10.1080\/03639045.2018.1492605","journal-title":"Drug Dev Ind Pharm"},{"key":"23043_CR45","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1016\/j.jacc.2016.03.567","volume":"67","author":"SS Gidding","year":"2016","unstructured":"Gidding SS (2016) Familial Hypercholesterolemia: now part of cardiovascular disease genetic epidemiology research. J Am Coll Cardiol 67:2590\u20132592. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.567","journal-title":"J Am Coll Cardiol"},{"key":"23043_CR46","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.2174\/1389201021666200519133350","volume":"21","author":"GN Girgis","year":"2020","unstructured":"Girgis GN (2020) Formulation and evaluation of Atorvastatin calcium-poly-\u03b5-caprolactone nanoparticles loaded ocular inserts for sustained release and antiinflammatory efficacy. Curr Pharm Biotechnol 21:1688\u20131698. https:\/\/doi.org\/10.2174\/1389201021666200519133350","journal-title":"Curr Pharm Biotechnol"},{"key":"23043_CR47","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1586\/erc.10.82","volume":"8","author":"AM Gotto Jr","year":"2010","unstructured":"Gotto AM Jr, Moon J (2010) Pitavastatin for the treatment of primary Hyperlipidemia and mixed dyslipidemia. Expert Rev Cardiovasc Ther 8:1079\u20131090. https:\/\/doi.org\/10.1586\/erc.10.82","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"23043_CR48","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2007.05.012","volume":"29","author":"AL Gould","year":"2007","unstructured":"Gould AL, Davies GM, Alemao E, Yin DD, Cook JR (2007) Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther 29:778\u2013794. https:\/\/doi.org\/10.1016\/j.clinthera.2007.05.012","journal-title":"Clin Ther"},{"key":"23043_CR49","doi-asserted-by":"publisher","first-page":"114700","DOI":"10.1016\/j.molliq.2020.114700","volume":"324","author":"M Guo","year":"2021","unstructured":"Guo M, Chen H, Zhang C, Zhang G, Wang Y, Li P, Fu Q (2021) Probing the particle shape effects on the biodistribution and antihyperlipidemic efficiency for oral lovastatin nanocrystals. J Mol Liq 324:114700. https:\/\/doi.org\/10.1016\/j.molliq.2020.114700","journal-title":"J Mol Liq"},{"key":"23043_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/2211352516666180629124433","volume":"17","author":"M Gupta","year":"2019","unstructured":"Gupta M, Kumar A (2019) Comparison of minimum inhibitory concentration (MIC) value of statin drugs: a systematic review. Antiinfect Agents 17:4\u201319. https:\/\/doi.org\/10.2174\/2211352516666180629124433","journal-title":"Antiinfect Agents"},{"key":"23043_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13596-019-00359-z","volume":"19","author":"M Gupta","year":"2019","unstructured":"Gupta M, Sharma R, Kumar A (2019) Comparative potential of simvastatin, Rosuvastatin and Fluvastatin against bacterial infection: an in silico and in vitro study. Orient Pharm Exp Med 19:259\u2013275. https:\/\/doi.org\/10.1007\/s13596-019-00359-z","journal-title":"Orient Pharm Exp Med"},{"key":"23043_CR52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1680\/jbibn.19.00006","volume":"9","author":"MK Haidar","year":"2019","unstructured":"Haidar MK, Demirbolat GM, Timur SS, G\u00fcrsoy RN, Nemutlu E, Ulubayram K, \u00d6ner L, Ero\u011flu H (2019) Atorvastatin-loaded nanosprayed chitosan nanoparticles for peripheral nerve injury. Bioinspired Biomim Nanobiomaterials 9:74\u201384. https:\/\/doi.org\/10.1680\/jbibn.19.00006","journal-title":"Bioinspired Biomim Nanobiomaterials"},{"key":"23043_CR53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00003088-200039060-00002","volume":"39","author":"T Hatanaka","year":"2000","unstructured":"Hatanaka T (2000) Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 39:397\u2013412. https:\/\/doi.org\/10.2165\/00003088-200039060-00002","journal-title":"Clin Pharmacokinet"},{"key":"23043_CR54","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","volume":"16","author":"T Hirota","year":"2020","unstructured":"Hirota T, Fujita Y, Ieiri I (2020) An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol 16:809\u2013822. https:\/\/doi.org\/10.1080\/17425255.2020.1801634","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"23043_CR55","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.ijbiomac.2017.10.086","volume":"107","author":"MR Hirpara","year":"2018","unstructured":"Hirpara MR, Manikkath J, Sivakumar K, Managuli RS, Gourishetti K, Krishnadas N, Shenoy RR, Jayaprakash B, Rao CM, Mutalik S (2018) Long circulating PEGylated-chitosan nanoparticles of rosuvastatin calcium: development and in vitro and in vivo evaluations. Int J Biol Macromol 107:2190\u20132200. https:\/\/doi.org\/10.1016\/j.ijbiomac.2017.10.086","journal-title":"Int J Biol Macromol"},{"key":"23043_CR56","doi-asserted-by":"publisher","first-page":"101746","DOI":"10.1016\/j.jddst.2020.101746","volume":"57","author":"KM Hosny","year":"2020","unstructured":"Hosny KM, Alharbi WS, Almehmady AM, Bakhaidar RB, Alkhalidi HM, Sindi AM, Hariri AH, Shadab MD, Zaki RM (2020) Preparation and optimization of pravastatin-naringenin nanotransfersomes to enhance bioavailability and reduce hepatic side effects. J Drug Deliv Sci Technol 57:101746. https:\/\/doi.org\/10.1016\/j.jddst.2020.101746","journal-title":"J Drug Deliv Sci Technol"},{"key":"23043_CR57","first-page":"18","volume":"5","author":"K Jain","year":"2013","unstructured":"Jain K, Kumar RS, Sood S, Gowthamarajan K (2013) Enhanced oral bioavailability of atorvastatin via oil-in-water nanoemulsion using aqueous titration method. J Pharm Sci Res 5:18","journal-title":"J Pharm Sci Res"},{"key":"23043_CR58","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1016\/j.bmc.2007.04.031","volume":"15","author":"KS Jain","year":"2007","unstructured":"Jain KS, Kathiravan MK, Somani RS, Shishoo CJ (2007) The biology and chemistry of Hyperlipidemia. Bioorg Med Chem 15:4674\u20134699. https:\/\/doi.org\/10.1016\/j.bmc.2007.04.031","journal-title":"Bioorg Med Chem"},{"key":"23043_CR59","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1161\/circulationaha.113.002870","volume":"129","author":"S Katsuki","year":"2014","unstructured":"Katsuki S, Matoba T, Nakashiro S, Sato K, Koga JI, Nakano K, Nakano Y, Egusa S, Sunagawa K, Egashira K (2014) Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization\/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 129:896\u2013906. https:\/\/doi.org\/10.1161\/circulationaha.113.002870","journal-title":"Circulation"},{"key":"23043_CR60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/03639045.2015.1040414","volume":"42","author":"S Khan","year":"2016","unstructured":"Khan S, Baboota S, Ali J, Narang RS, Narang JK (2016) Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation. Drug Dev Ind Pharm 42:209\u2013220. https:\/\/doi.org\/10.3109\/03639045.2015.1040414","journal-title":"Drug Dev Ind Pharm"},{"key":"23043_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.021","volume":"331","author":"J Kreuter","year":"2007","unstructured":"Kreuter J (2007) Nanoparticles-a historical perspective. Int J Pharm 331:1\u201310. https:\/\/doi.org\/10.1016\/j.ijpharm.2006.10.021","journal-title":"Int J Pharm"},{"key":"23043_CR62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.22270\/jddt.v11i2.4578","volume":"11","author":"A Kumar","year":"2021","unstructured":"Kumar A, Jain UK, Patel A (2021) Formulation development and evaluation of liposphere of poor water soluble drug for Hyperlipidemia. J Drug Deliv Ther 11:23\u201330. https:\/\/doi.org\/10.22270\/jddt.v11i2.4578","journal-title":"J Drug Deliv Ther"},{"key":"23043_CR63","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/IJN.S77731","volume":"10","author":"M Kurakula","year":"2015","unstructured":"Kurakula M, El-Helw AM, Sobahi TR, Abdelaal MY (2015) Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy. Int J Nanomedicine 10:321. https:\/\/doi.org\/10.2147\/IJN.S77731","journal-title":"Int J Nanomedicine"},{"key":"23043_CR64","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jacl.2017.06.016","volume":"11","author":"M Lazo-Porras","year":"2017","unstructured":"Lazo-Porras M, Bernabe-Ortiz A, Quispe R, M\u00e1laga G, Smeeth L, Gilman RH, Checkley W, Miranda JJ, Cronicas Cohort Study Group (2017) Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles. J Clin Lipidol 11:1212\u20131222. https:\/\/doi.org\/10.1016\/j.jacl.2017.06.016","journal-title":"J Clin Lipidol"},{"key":"23043_CR65","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lfs.2014.10.003","volume":"118","author":"Y Li","year":"2014","unstructured":"Li Y, Qin G, Liu J, Mao L, Zhang Z, Shang J (2014) Adipose tissue regulates hepatic cholesterol metabolism via adiponectin. Life Sci 118:27\u201333. https:\/\/doi.org\/10.1016\/j.lfs.2014.10.003","journal-title":"Life Sci"},{"key":"23043_CR66","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.2165\/00003495-200161120-00012","volume":"61","author":"HS Malhotra","year":"2001","unstructured":"Malhotra HS, Goa KL (2001) Atorvastatin Drugs 61:1835\u20131881. https:\/\/doi.org\/10.2165\/00003495-200161120-00012","journal-title":"Atorvastatin Drugs"},{"key":"23043_CR67","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/01.cir.101.2.207","volume":"101","author":"DJ Maron","year":"2000","unstructured":"Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207\u2013213. https:\/\/doi.org\/10.1161\/01.cir.101.2.207","journal-title":"Circulation"},{"key":"23043_CR68","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3109\/1061186X.2016.1172586","volume":"24","author":"M Mathur","year":"2016","unstructured":"Mathur M, Devi VK (2016) Potential of novel drug delivery strategies for the treatment of Hyperlipidemia. J Drug Target 24:916\u2013926. https:\/\/doi.org\/10.3109\/1061186X.2016.1172586","journal-title":"J Drug Target"},{"key":"23043_CR69","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.numecd.2019.09.008","volume":"30","author":"C Mattiuzzi","year":"2020","unstructured":"Mattiuzzi C, Sanchis-Gomar F, Lippi G (2020) Worldwide burden of LDL cholesterol: Implications in cardiovascular disease. Nutr Metab Cardiovasc Dis 30:241\u2013244. https:\/\/doi.org\/10.1016\/j.numecd.2019.09.008","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"23043_CR70","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/MED.0000000000000590","volume":"28","author":"F Mohamed","year":"2021","unstructured":"Mohamed F, Seedat F, Raal FJ (2021) Novel therapies for familial hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes 28:188\u2013195. https:\/\/doi.org\/10.1097\/MED.0000000000000590","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"23043_CR71","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4314\/tjpr.v5i1.14634","volume":"5","author":"VJ Mohanraj","year":"2006","unstructured":"Mohanraj VJ, Chen Y (2006) Nanoparticles-a review. Trop J. Pharm Res 5:561\u2013573. https:\/\/doi.org\/10.4314\/tjpr.v5i1.14634","journal-title":"Pharm Res"},{"key":"23043_CR72","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1089\/15246090260137590","volume":"11","author":"LJ Mosca","year":"2002","unstructured":"Mosca LJ (2002) Contemporary management of hyperlipidemia in women. J Womens Health Gend Based Med 11:423\u2013432. https:\/\/doi.org\/10.1089\/15246090260137590","journal-title":"J Womens Health Gend Based Med"},{"key":"23043_CR73","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.biotechadv.2015.04.001","volume":"33","author":"KC Mulder","year":"2015","unstructured":"Mulder KC, Mulinari F, Franco OL, Soares MS, Magalh\u00e3es BS, Parachin NS (2015) Lovastatin production: From molecular basis to industrial process optimization. Biotechnol Adv 33:648\u2013665. https:\/\/doi.org\/10.1016\/j.biotechadv.2015.04.001","journal-title":"Biotechnol Adv"},{"key":"23043_CR74","first-page":"914","volume":"4","author":"B Narasimharao","year":"2015","unstructured":"Narasimharao B, Viswanath V, Purushothaman M, Sreevani S, Sowjanya G (2015) Effect of different stabilizers on the formulation of simvastatin nanosuspension prepared by precipitation ultrasonication technique. World J Pharm Res 4:914\u2013925","journal-title":"World J Pharm Res"},{"key":"23043_CR75","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/circulationaha.114.012477","volume":"131","author":"AM Navar-Boggan","year":"2015","unstructured":"Navar-Boggan AM, Peterson ED, D\u2019Agostino RB Sr, Neely B, Sniderman AD, Pencina MJ (2015) Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation 131:451\u2013458. https:\/\/doi.org\/10.1161\/circulationaha.114.012477","journal-title":"Circulation"},{"key":"23043_CR76","doi-asserted-by":"publisher","first-page":"e004909","DOI":"10.1161\/JAHA.116.004909","volume":"6","author":"T Okerson","year":"2017","unstructured":"Okerson T, Patel J, DiMario S, Burton T, Seare J, Harrison DJ (2017) Effect of 2013 ACC\/AHA blood cholesterol guidelines on statin treatment patterns and low-density lipoprotein cholesterol in atherosclerotic cardiovascular disease patients. J Am Heart Assoc 6:e004909. https:\/\/doi.org\/10.1161\/JAHA.116.004909","journal-title":"J Am Heart Assoc"},{"key":"23043_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1034\/j.1399-0012.2003.02042.x","volume":"17","author":"A Oliveras","year":"2003","unstructured":"Oliveras A, Roquer J, Puig JM, Rodr\u00edguez A, Mir M, Orfila MA, Masramon J, Lloveras J (2003) Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. Clin Transplant 17:1\u20138. https:\/\/doi.org\/10.1034\/j.1399-0012.2003.02042.x","journal-title":"Clin Transplant"},{"key":"23043_CR78","doi-asserted-by":"publisher","first-page":"93","DOI":"10.9790\/0853-1410693100","volume":"14","author":"PE Onwe","year":"2015","unstructured":"Onwe PE, Folawiyo MA, Anyigor-Ogah CS, Umahi G, Okorocha AE, Afoke A (2015) Hyperlipidemia: etiology and possible control. IOSR J Dent Med Sci 14:93\u2013100. https:\/\/doi.org\/10.9790\/0853-1410693100","journal-title":"IOSR J Dent Med Sci"},{"key":"23043_CR79","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1567-5688(09)71816-1","volume":"10","author":"E Ors\u00f3","year":"2009","unstructured":"Ors\u00f3 E, Ahrens N, Schmitz G (2009) Familial hypercholesterolemia and lipoprotein (a) Hyperlipidemia as independent and combined cardiovascular risk factors. Atheroscler Suppl 10:74\u201378. https:\/\/doi.org\/10.1016\/S1567-5688(09)71816-1","journal-title":"Atheroscler Suppl"},{"key":"23043_CR80","first-page":"591","volume":"75","author":"SG Padhye","year":"2013","unstructured":"Padhye SG, Nagarsenker MS (2013) Simvastatin solid lipid nanoparticles for oral delivery: formulation development and in vivo evaluation. Indian J Pharm Sci 75:591","journal-title":"Indian J Pharm Sci"},{"key":"23043_CR81","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4172\/pharmaceutical-sciences.1000375","volume":"80","author":"S Pallavi","year":"2018","unstructured":"Pallavi S, Patil SV, Patil SS, Shinde S (2018) Preparation and evaluation of mucoadhesive nanoparticles of rosuvastatin. Indian J Pharm Sci 80:428\u2013433. https:\/\/doi.org\/10.4172\/pharmaceutical-sciences.1000375","journal-title":"Indian J Pharm Sci"},{"key":"23043_CR82","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1517\/14728214.2010.481282","volume":"15","author":"C Paras","year":"2010","unstructured":"Paras C, Hussain MM, Rosenson RS (2010) Emerging drugs for Hyperlipidemia. Expert Opin Emerg Drugs 15:433\u2013451. https:\/\/doi.org\/10.1517\/14728214.2010.481282","journal-title":"Expert Opin Emerg Drugs"},{"key":"23043_CR83","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.13040\/IJPSR.0975-8232","volume":"7","author":"P Parashar","year":"2016","unstructured":"Parashar P, Mangla B, Joshi SK (2016) Design & development of novel lipid based carrier system for delivery of pitavastatin calcium. Int J Pharm Sci Res 7:5030. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232","journal-title":"Int J Pharm Sci Res"},{"key":"23043_CR84","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4274\/tjps.galenos.2020.65047","volume":"18","author":"AS Patil","year":"2021","unstructured":"Patil AS, Hegde R, Gadad AP, Dandagi PM, Masareddy R, Bolmal U (2021) Exploring the solvent-anti-solvent method of nanosuspension for enhanced oral bioavailability of lovastatin. Turk J Pharm Sci 18:541. https:\/\/doi.org\/10.4274\/tjps.galenos.2020.65047","journal-title":"Turk J Pharm Sci"},{"key":"23043_CR85","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1517\/14656566.5.12.2583","volume":"5","author":"TR Pedersen","year":"2004","unstructured":"Pedersen TR, Tobert JA (2004) Simvastatin: a review. Expert Opin Pharmacother 5:2583\u20132596. https:\/\/doi.org\/10.1517\/14656566.5.12.2583","journal-title":"Expert Opin Pharmacother"},{"key":"23043_CR86","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40005-017-0342-8","volume":"48","author":"V Pokharkar","year":"2018","unstructured":"Pokharkar V, Patil-Gadhe A, Kaur G (2018) Physicochemical and pharmacokinetic evaluation of rosuvastatin loaded nanostructured lipid carriers: Influence of long-and medium-chain fatty acid mixture. J Pharm Investig 48:465\u2013476. https:\/\/doi.org\/10.1007\/s40005-017-0342-8","journal-title":"J Pharm Investig"},{"key":"23043_CR87","first-page":"744","volume":"5","author":"E Priyanka","year":"2018","unstructured":"Priyanka E, Sundari PT (2018) Formulation and evaluation of simvastatin loaded gelatin nanoparticles. IJRAR 5:744\u2013753","journal-title":"IJRAR"},{"key":"23043_CR88","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/1871526518666180806123230","volume":"19","author":"R Rana","year":"2019","unstructured":"Rana R, Sharma R, Kumar A (2019a) Repurposing of existing statin drugs for treatment of microbial infections: how much promising? Infect Disord Drug Targets 19:224\u2013237. https:\/\/doi.org\/10.2174\/1871526518666180806123230","journal-title":"Infect Disord Drug Targets"},{"key":"23043_CR89","doi-asserted-by":"publisher","first-page":"506","DOI":"10.2174\/1566524019666190520094644","volume":"19","author":"R Rana","year":"2019","unstructured":"Rana R, Sharma R, Kumar A (2019b) Repurposing of Fluvastatin against Candida albicans CYP450 lanosterol 14 \u03b1-demethylase, a target enzyme for antifungal therapy: an In silico and In vitro study. Curr Mol Med 19:506\u2013524. https:\/\/doi.org\/10.2174\/1566524019666190520094644","journal-title":"Curr Mol Med"},{"key":"23043_CR90","doi-asserted-by":"publisher","first-page":"452","DOI":"10.4103\/0378-6323.55387","volume":"75","author":"N Ranjan","year":"2009","unstructured":"Ranjan N (2009) Management of hyperlipidemias: an update. Indian J Dermatol Venereol Leprol 75:452\u2013462. https:\/\/doi.org\/10.4103\/0378-6323.55387","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"23043_CR91","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/10837450.2018.1484765","volume":"24","author":"M Rezazadeh","year":"2019","unstructured":"Rezazadeh M, Parandeh M, Akbari V, Ebrahimi Z, Taheri A (2019) Incorporation of rosuvastatin-loaded chitosan\/chondroitin sulfate nanoparticles into a thermosensitive hydrogel for bone tissue engineering: preparation, characterization, and cellular behavior. Pharm Dev Technol 24:357\u2013367. https:\/\/doi.org\/10.1080\/10837450.2018.1484765","journal-title":"Pharm Dev Technol"},{"key":"23043_CR92","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijpharm.2019.02.002","volume":"560","author":"SZ Rizvi","year":"2019","unstructured":"Rizvi SZ, Shah FA, Khan N, Muhammad I, Ali KH, Ansari MM, Din FUD, Qureshi OS, Kim KW, Choe YH, Kim JK (2019) Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in Hyperlipidemia animal model. Int J Pharm 560:136\u2013143. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.02.002","journal-title":"Int J Pharm"},{"key":"23043_CR93","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1161\/01.ATV.0000166548.65753.1e","volume":"25","author":"LL Rudel","year":"2005","unstructured":"Rudel LL, Lee RG, Parini P (2005) ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler Thromb Vasc Biol 25:1112\u20131118. https:\/\/doi.org\/10.1161\/01.ATV.0000166548.65753.1e","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"23043_CR94","first-page":"125","volume":"4","author":"AN Sabour","year":"2020","unstructured":"Sabour AN, Mtashar ZZ (2020) Effect of simvastatin nanohybrid drug on liver tissue and some of oxidation indicators in white male rats induced with Hyperlipidemia. Sci J Med Res 4:125\u2013133","journal-title":"Sci J Med Res"},{"key":"23043_CR95","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1567-5688(11)70886-8","volume":"12","author":"Y Saito","year":"2011","unstructured":"Saito Y (2011) Pitavastatin: an overview. Atheroscler Suppl 12:271\u2013276. https:\/\/doi.org\/10.1016\/S1567-5688(11)70886-8","journal-title":"Atheroscler Suppl"},{"key":"23043_CR96","first-page":"525","volume":"5","author":"OS Salih","year":"2013","unstructured":"Salih OS, Samein LH, Ali WK (2013) Formulation and in vitro evaluation of rosuvastatin calcium niosomes. Int J Pharm Pharm Sci 5:525\u2013535","journal-title":"Int J Pharm Pharm Sci"},{"key":"23043_CR97","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3389\/fendo.2020.00616","volume":"11","author":"L Santos-Baez","year":"2020","unstructured":"Santos-Baez L, Ginsberg HN (2020) Hypertriglyceridemia-causes, significance, and approaches to therapy. Front Endocrinol 11:616. https:\/\/doi.org\/10.3389\/fendo.2020.00616","journal-title":"Front Endocrinol"},{"key":"23043_CR98","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11789-015-0074-0","volume":"10","author":"G Schmitz","year":"2015","unstructured":"Schmitz G, Ors\u00f3 E (2015) Lipoprotein (a) Hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. Clin Res Cardiol Suppl 10:21\u201325. https:\/\/doi.org\/10.1007\/s11789-015-0074-0","journal-title":"Clin Res Cardiol Suppl"},{"key":"23043_CR99","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/00129784-200404020-00005","volume":"4","author":"LJ Scott","year":"2004","unstructured":"Scott LJ, Curran MP, Figgitt DP (2004) Rosuvastatin. Am J Cardiovasc Drugs 4:117\u2013138. https:\/\/doi.org\/10.2165\/00129784-200404020-00005","journal-title":"Am J Cardiovasc Drugs"},{"key":"23043_CR100","doi-asserted-by":"publisher","first-page":"701","DOI":"10.4103\/0250-474X.49087","volume":"70","author":"A Seenivasan","year":"2008","unstructured":"Seenivasan A, Subhagar S, Aravindan R, Viruthagiri T (2008) Microbial production and biomedical applications of lovastatin. Indian J Pharm Sci 70:701. https:\/\/doi.org\/10.4103\/0250-474X.49087","journal-title":"Indian J Pharm Sci"},{"key":"23043_CR101","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.carbpol.2017.01.038","volume":"163","author":"N Selvasudha","year":"2017","unstructured":"Selvasudha N, Koumaravelou K (2017) The multifunctional synergistic effect of chitosan on simvastatin loaded nanoparticulate drug delivery system. Carbohydr Polym 163:70\u201380. https:\/\/doi.org\/10.1016\/j.carbpol.2017.01.038","journal-title":"Carbohydr Polym"},{"key":"23043_CR102","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3109\/10717544.2014.920937","volume":"23","author":"K Sharma","year":"2016","unstructured":"Sharma K, Kumar K, Mishra N (2016a) Nanoparticulate carrier system: a novel treatment approach for Hyperlipidemia. Drug Deliv 23:684\u2013699. https:\/\/doi.org\/10.3109\/10717544.2014.920937","journal-title":"Drug Deliv"},{"key":"23043_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-52645-0","volume":"9","author":"M Sharma","year":"2019","unstructured":"Sharma M, Mehta I (2019) Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential. Sci Rep 9:1\u201311. https:\/\/doi.org\/10.1038\/s41598-019-52645-0","journal-title":"Sci Rep"},{"key":"23043_CR104","doi-asserted-by":"publisher","first-page":"14225","DOI":"10.33263\/BRIAC116.1422514239","volume":"11","author":"N Sharma","year":"2021","unstructured":"Sharma N, Behl T, Singh S, Bansal A, Singh SK, Zahoor I (2021) Expatiating the therapeutic profile of Garlic (Allium sativum): a bench to bedside approach. Biointerface Res Appl Chem 11:14225\u201314239. https:\/\/doi.org\/10.33263\/BRIAC116.1422514239","journal-title":"Biointerface Res Appl Chem"},{"key":"23043_CR105","first-page":"4074","volume":"4","author":"S Sharma","year":"2011","unstructured":"Sharma S, Sharma A, Arora S, Gupta A (2011) Preparation, characterization, in vitro & in vivo evaluation of elastic liposomal formulation of lovastatin. J Pharm Res 4:4074","journal-title":"J Pharm Res"},{"key":"23043_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21276\/ijlssr.2016.2.4.23","volume":"2","author":"Y Sharma","year":"2016","unstructured":"Sharma Y, Kumar K, Padhy SK (2016) Formulation and evaluation of Atorvastatin calcium niosomes. Int J Life Sci Scienti Res 2:1\u20134. https:\/\/doi.org\/10.21276\/ijlssr.2016.2.4.23","journal-title":"Int J Life Sci Scienti Res"},{"key":"23043_CR107","doi-asserted-by":"publisher","first-page":"399","DOI":"10.13005\/bpj\/504","volume":"7","author":"GF Shattat","year":"2015","unstructured":"Shattat GF (2015) A review article on hyperlipidemia: types, treatments and new drug targets. Biomed Pharmacol J 7:399\u2013409. https:\/\/doi.org\/10.13005\/bpj\/504","journal-title":"Biomed Pharmacol J"},{"key":"23043_CR108","first-page":"2459","volume":"7","author":"RL Shid","year":"2014","unstructured":"Shid RL, Dhole SN, Kulkarni N, Shid SL (2014) Formulation and evaluation of nanosuspension delivery system for simvastatin. Int J Pharm Sci Nanotechnol 7:2459\u20132476","journal-title":"Int J Pharm Sci Nanotechnol"},{"key":"23043_CR109","first-page":"1055","volume":"6","author":"H Singh","year":"2017","unstructured":"Singh H, Gupta RD, Gautam G (2017) Preparation and optimization of rosuvastatin calcium loaded solid lipid nanoparticles by central composite design. World J Pharm Res 6:1055\u20131071","journal-title":"World J Pharm Res"},{"key":"23043_CR110","doi-asserted-by":"publisher","first-page":"436","DOI":"10.22159\/ajpcr.2018.v11i7.26177","volume":"11","author":"HA Singh","year":"2018","unstructured":"Singh HA, Gupta RD, Gautam GI (2018) Formulation development, characterization, and in vitro-in vivo study of antihyperlipidemic drug rosuvastatin calcium-solid lipid nanoparticles. Asian J Pharm Clin Res 11:436\u2013443. https:\/\/doi.org\/10.22159\/ajpcr.2018.v11i7.26177","journal-title":"Asian J Pharm Clin Res"},{"key":"23043_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1871-5125(10)35001-1","volume":"35","author":"VM Sonje","year":"2010","unstructured":"Sonje VM, Kumar L, Meena CL, Kohli G, Puri V, Jain R, Bansal AK, Brittain HG (2010) Atorvastatin calcium. Profiles Drug Subst Excip Relat Methodol 35:1\u201370. https:\/\/doi.org\/10.1016\/S1871-5125(10)35001-1","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"23043_CR112","doi-asserted-by":"publisher","first-page":"271","DOI":"10.15171\/apb.2019.031","volume":"9","author":"R Sreedhar","year":"2019","unstructured":"Sreedhar R, Kumar VS, Pillai AK, Mangalathillam S (2019) Omega-3 fatty acid based nanolipid formulation of atorvastatin for treating Hyperlipidemia. Adv Pharm Bull 9:271. https:\/\/doi.org\/10.15171\/apb.2019.031","journal-title":"Adv Pharm Bull"},{"key":"23043_CR113","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1058-9813(00)00075-8","volume":"12","author":"TJ Starc","year":"2001","unstructured":"Starc TJ (2001) Management of hyperlipidemia in children. Prog Pediatr Cardiol 12:205\u2013213. https:\/\/doi.org\/10.1016\/S1058-9813(00)00075-8","journal-title":"Prog Pediatr Cardiol"},{"key":"23043_CR114","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1542\/pir.2019-0053","volume":"41","author":"J Stewart","year":"2020","unstructured":"Stewart J, McCallin T, Martinez J, Chacko S, Yusuf S (2020) Hyperlipidemia. Pediatr Rev 41:393\u2013402. https:\/\/doi.org\/10.1542\/pir.2019-0053","journal-title":"Pediatr Rev"},{"key":"23043_CR115","doi-asserted-by":"publisher","unstructured":"Su L, Mittal R, Ramgobin D, Jain R, Jain R (2021) Current management guidelines on hyperlipidemia: The silent killer. J Lipids 2021.\u00a0https:\/\/doi.org\/10.1155\/2021\/9883352","DOI":"10.1155\/2021\/9883352"},{"key":"23043_CR116","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/03639045.2016.1232726","volume":"43","author":"D Suares","year":"2017","unstructured":"Suares D, Prabhakar B (2017) Cuboidal lipid polymer nanoparticles of rosuvastatin for oral delivery. Drug Dev Ind Pharm 43:213\u2013224. https:\/\/doi.org\/10.1080\/03639045.2016.1232726","journal-title":"Drug Dev Ind Pharm"},{"key":"23043_CR117","doi-asserted-by":"publisher","unstructured":"Subramanian S (2016) Preparation, evaluation, and optimization of atorvastatin nanosuspension incorporated transdermal patch. Asian J Pharm 10. https:\/\/doi.org\/10.22377\/ajp.v10i04.882","DOI":"10.22377\/ajp.v10i04.882"},{"key":"23043_CR118","doi-asserted-by":"publisher","first-page":"77","DOI":"10.31083\/j.rcm.2018.03.908","volume":"19","author":"S Sudhakaran","year":"2018","unstructured":"Sudhakaran S, Bottiglieri T, Tecson KM, Kluger AY, McCullough PA (2018) Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions. Rev Cardiovasc Med 19:77\u201388. https:\/\/doi.org\/10.31083\/j.rcm.2018.03.908","journal-title":"Rev Cardiovasc Med"},{"key":"23043_CR119","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.3892\/etm.2020.8632","volume":"19","author":"Y Sun","year":"2020","unstructured":"Sun Y, Chen L, Zhao S, Shi L, Li H, Tian W, Qi G (2020) Effects of nanoparticle-mediated delivery of pitavastatin on atherosclerotic plaques in ApoE-knockout mice and THP-1-derived macrophages. Exp Ther Med 19:3787\u20133797. https:\/\/doi.org\/10.3892\/etm.2020.8632","journal-title":"Exp Ther Med"},{"key":"23043_CR120","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1208\/pt0801024","volume":"8","author":"G Suresh","year":"2007","unstructured":"Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V (2007) Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 8:E162\u2013E170. https:\/\/doi.org\/10.1208\/pt0801024","journal-title":"AAPS PharmSciTech"},{"key":"23043_CR121","first-page":"2779","volume":"9","author":"G Suvarna","year":"2015","unstructured":"Suvarna G, Narender D, Kishan V (2015) Preparation, characterization and in vivo evaluation of rosuvastatin calcium loaded solid lipid nanoparticles. Int J Pharm Sci Nanotech 9:2779\u20132785","journal-title":"Int J Pharm Sci Nanotech"},{"key":"23043_CR122","doi-asserted-by":"publisher","unstructured":"Taghizadeh E, Farahani N, Mardani R, Taheri F, Taghizadeh H, Gheibihayat SM (2021) Genetics of familial combined hyperlipidemia (FCHL) disorder: an update. Biochem Genet 1-29.https:\/\/doi.org\/10.1007\/s10528-021-10130-2","DOI":"10.1007\/s10528-021-10130-2"},{"key":"23043_CR123","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1586\/14779072.6.3.369","volume":"6","author":"LR Tannock","year":"2008","unstructured":"Tannock LR (2008) Advances in the management of hyperlipidemia-induced atherosclerosis. Expert Rev Cardiovasc Ther 6:369\u2013383. https:\/\/doi.org\/10.1586\/14779072.6.3.369","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"23043_CR124","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijpharm.2015.02.012","volume":"483","author":"SA Tayel","year":"2015","unstructured":"Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH (2015) Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. Int J Pharm 483:77\u201388. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.02.012","journal-title":"Int J Pharm"},{"key":"23043_CR125","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5551\/jat.E590","volume":"15","author":"T Teramoto","year":"2008","unstructured":"Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K (2008) Primary Hyperlipidemia. J Atheroscler Thromb 15:49\u201351. https:\/\/doi.org\/10.5551\/jat.E590","journal-title":"J Atheroscler Thromb"},{"key":"23043_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-57666-8","volume":"10","author":"H Thai","year":"2020","unstructured":"Thai H, Nguyen CT, Thach LT, Tran MT, Mai HD, Nguyen TT, Le GD, Van Can M, Dai Tran L, Bach GL, Ramadass K (2020) Characterization of chitosan\/alginate\/lovastatin nanoparticles and investigation of their toxic effects in vitro and in vivo. Sci Rep 10:1\u20135. https:\/\/doi.org\/10.1038\/s41598-020-57666-8","journal-title":"Sci Rep"},{"key":"23043_CR127","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrd1112","volume":"2","author":"JA Tobert","year":"2003","unstructured":"Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2:517\u2013526. https:\/\/doi.org\/10.1038\/nrd1112","journal-title":"Nat Rev Drug Discov"},{"key":"23043_CR128","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1067\/mda.2001.118859","volume":"47","author":"PP Toth","year":"2001","unstructured":"Toth PP (2001) High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects. Dis Mon 47:365\u2013416. https:\/\/doi.org\/10.1067\/mda.2001.118859","journal-title":"Dis Mon"},{"key":"23043_CR129","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PL, Nora C, Yeang C, Witztum JL (2020) Statin therapy increases lipoprotein (a) levels. Eur Heart J 41:2275\u20132284. https:\/\/doi.org\/10.1093\/eurheartj\/ehz310","journal-title":"Eur Heart J"},{"key":"23043_CR130","doi-asserted-by":"publisher","unstructured":"Vo-An Q, Nguyen TC, Nguyen QT, Vu QT, Truong CD, Nguyen TL, Ly TN, Bach LG, Thai H (2021) Novel nanoparticle biomaterial of alginate\/chitosan loading simultaneously lovastatin and ginsenoside RB1: characteristics, morphology, and drug release study. Int J Polym Sci 2021.\u00a0https:\/\/doi.org\/10.1155\/2021\/5214510","DOI":"10.1155\/2021\/5214510"},{"key":"23043_CR131","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1001\/jama.291.18.2243","volume":"291","author":"JM Walsh","year":"2004","unstructured":"Walsh JM, Pignone M (2004) Drug treatment of Hyperlipidemia in women. JAMA 291:2243\u20132252. https:\/\/doi.org\/10.1001\/jama.291.18.2243","journal-title":"JAMA"},{"key":"23043_CR132","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/hrt.2010.204990","volume":"97","author":"GF Watts","year":"2011","unstructured":"Watts GF, Karpe F (2011) Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 97:350\u2013356. https:\/\/doi.org\/10.1136\/hrt.2010.204990","journal-title":"Heart"},{"key":"23043_CR133","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0165-6147(02)02077-1","volume":"23","author":"G Weitz-Schmidt","year":"2002","unstructured":"Weitz-Schmidt G (2002) Statins as anti-inflammatory agents. Trends Pharmacol Sci 23:482\u2013487. https:\/\/doi.org\/10.1016\/S0165-6147(02)02077-1","journal-title":"Trends Pharmacol Sci"},{"key":"23043_CR134","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/009127000204200902","volume":"42","author":"CM White","year":"2002","unstructured":"White CM (2002) A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 42:963\u2013970. https:\/\/doi.org\/10.1177\/009127000204200902","journal-title":"J Clin Pharmacol"},{"key":"23043_CR135","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cll.2013.11.010","volume":"34","author":"AH Wu","year":"2014","unstructured":"Wu AH (2014) Biomarkers for cholesterol absorption and synthesis in hyperlipidemic patients: role for therapeutic selection. Clin Lab Med 34:157\u2013166. https:\/\/doi.org\/10.1016\/j.cll.2013.11.010","journal-title":"Clin Lab Med"},{"key":"23043_CR136","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2337\/db16-0046","volume":"65","author":"C Xiao","year":"2016","unstructured":"Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF (2016) Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes 65:1767\u20131778. https:\/\/doi.org\/10.2337\/db16-0046","journal-title":"Diabetes"},{"key":"23043_CR137","doi-asserted-by":"publisher","first-page":"110585","DOI":"10.1016\/j.fct.2019.110585","volume":"131","author":"Z Xiong","year":"2019","unstructured":"Xiong Z, Cao X, Wen Q, Chen Z, Cheng Z, Huang X, Zhang Y, Long C, Zhang Y, Huang Z (2019) An overview of the bioactivity of monacolin K\/lovastatin. Food Chem Toxicol 131:110585. https:\/\/doi.org\/10.1016\/j.fct.2019.110585","journal-title":"Food Chem Toxicol"},{"key":"23043_CR138","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0095-4543(05)70164-0","volume":"27","author":"JN Yu","year":"2000","unstructured":"Yu JN, Cunningham JA, Thouin SR, Gurvich T, Liu D (2000) Hyperlipidemia. Prim Care 27:541\u2013587. https:\/\/doi.org\/10.1016\/s0095-4543(05)70164-0","journal-title":"Prim Care"},{"key":"23043_CR139","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.2147\/DDDT.S90016","volume":"9","author":"J Zhou","year":"2015","unstructured":"Zhou J, Zhou D (2015) Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers. Drug Des Devel Ther 9:5269. https:\/\/doi.org\/10.2147\/DDDT.S90016","journal-title":"Drug Des Devel Ther"}],"container-title":["Environmental Science and Pollution Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-022-23043-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11356-022-23043-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-022-23043-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T07:54:45Z","timestamp":1666166085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11356-022-23043-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":139,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["23043"],"URL":"https:\/\/doi.org\/10.1007\/s11356-022-23043-3","relation":{},"ISSN":["0944-1344","1614-7499"],"issn-type":[{"value":"0944-1344","type":"print"},{"value":"1614-7499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors have approved the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}